360 related articles for article (PubMed ID: 32394316)
21. A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy.
Jang M; Han HD; Ahn HJ
Sci Rep; 2016 Aug; 6():32363. PubMed ID: 27562435
[TBL] [Abstract][Full Text] [Related]
22. A Review of pH-Responsive Organic-Inorganic Hybrid Nanoparticles for RNAi-Based Therapeutics.
Wang L; Yan Y
Macromol Biosci; 2021 Sep; 21(9):e2100183. PubMed ID: 34160896
[TBL] [Abstract][Full Text] [Related]
23. Delivering small interfering RNA for novel therapeutics.
Lu PY; Woodle MC
Methods Mol Biol; 2008; 437():93-107. PubMed ID: 18369963
[TBL] [Abstract][Full Text] [Related]
24. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
25. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges.
Won Lee J; Kyu Shim M; Kim H; Jang H; Lee Y; Hwa Kim S
Adv Drug Deliv Rev; 2023 Oct; 201():115073. PubMed ID: 37657644
[TBL] [Abstract][Full Text] [Related]
26. Current issues of RNAi therapeutics delivery and development.
Haussecker D
J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
[TBL] [Abstract][Full Text] [Related]
27. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.
Singh S; Narang AS; Mahato RI
Pharm Res; 2011 Dec; 28(12):2996-3015. PubMed ID: 22033880
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.
Babu A; Muralidharan R; Amreddy N; Mehta M; Munshi A; Ramesh R
IEEE Trans Nanobioscience; 2016 Dec; 15(8):849-863. PubMed ID: 28092499
[TBL] [Abstract][Full Text] [Related]
29. Polymer-based delivery of RNA-based therapeutics in ovarian cancer.
Weirauch U; Gutsch D; Höbel S; Aigner A
Methods Mol Biol; 2013; 1049():443-65. PubMed ID: 23913237
[TBL] [Abstract][Full Text] [Related]
30. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
31. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
32. In vivo delivery aspects of miRNA, shRNA and siRNA.
Khatri N; Rathi M; Baradia D; Trehan S; Misra A
Crit Rev Ther Drug Carrier Syst; 2012; 29(6):487-527. PubMed ID: 23176057
[TBL] [Abstract][Full Text] [Related]
33. Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for In Vivo Gene Silencing in Leukemia.
Lee DJ; Kessel E; Lehto T; Liu X; Yoshinaga N; Padari K; Chen YC; Kempter S; Uchida S; Rädler JO; Pooga M; Sheu MT; Kataoka K; Wagner E
Bioconjug Chem; 2017 Sep; 28(9):2393-2409. PubMed ID: 28772071
[TBL] [Abstract][Full Text] [Related]
34. Are Viral Vectors Any Good for RNAi Antiviral Therapy?
Lundstrom K
Viruses; 2020 Oct; 12(10):. PubMed ID: 33092124
[TBL] [Abstract][Full Text] [Related]
35. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.
Martirosyan A; Olesen MJ; Howard KA
Adv Genet; 2014; 88():325-52. PubMed ID: 25409611
[TBL] [Abstract][Full Text] [Related]
36. Editorial focus: understanding off-target effects as the key to successful RNAi therapy.
Bartoszewski R; Sikorski AF
Cell Mol Biol Lett; 2019; 24():69. PubMed ID: 31867046
[TBL] [Abstract][Full Text] [Related]
37. RNAi-based therapeutics-current status, challenges and prospects.
Tiemann K; Rossi JJ
EMBO Mol Med; 2009 Jun; 1(3):142-51. PubMed ID: 20049714
[TBL] [Abstract][Full Text] [Related]
38. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic face of RNAi: in vivo challenges.
Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
